Cyrill Zimmermann

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach that aims to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent.

Adamant is a specialist investment manager investing in the biotechnology, medical technology and specialty pharmaceuticals sectors. Within these sectors, they invest in European and US equity. The firm's investment philosophy emphasizes fundamental research and leveraging an active network of scientists, doctors and financial experts to profit from the growth of the biomedical market. The firm manages their three portfolio sectors complementarily, the biotechnology sector providing opportunities for growth, medical technology offering sustainability, and specialty pharmaceuticals supplying stability. Demographics and medical breakthroughs are the major factors influencing Adamant's investment approach, as well as fundamental financial analysis at the company level. The management team includes experienced biomedical specialists with industry, research and asset management backgrounds.